The effect of XXXX on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.

@entity1 @entity16503 @entity263 @entity1067
PURPOSE: We determined the effects of @entity16503 on transition and peripheral zone volume, and the clinical value of the transition zone index in @entity1 with @entity1067 . MATERIALS AND METHODS: A total of 2,802 @entity1 50 years or older with diagnosed @entity1067 , American Urological Association symptom index score 12 or greater, total prostate volume 30 cc or greater, prostate specific antigen 1.5 ng/ml or greater and 10 ng/ml or less, and peak urinary flow rate 15 ml per second or less were randomized to receive 0.5 mg @entity16503 daily or placebo for 2 years. Total prostate and transition zone volume was measured with transrectal ultrasound at baseline and 4 times during the 2-year period. Peripheral zone volume (total prostate volume minus transition zone volume) and the transition zone index (transition zone volume/total prostate volume) were calculated. @entity1 were stratified into tertiles according to baseline total prostate and transition zone volume, and the transition zone index. RESULTS: At 24 months @entity16503 significantly decreased total prostate volume from baseline (p <0.0001). There were similar decreases in transition and peripheral zone volume (approximately 25%). In @entity1 receiving placebo high baseline total prostate and transition zone volume, and transition zone index were associated with poor 2-year outcomes, ie a low peak urinary flow rate, high American Urological Association symptom index scores, and an increased frequency of acute urinary retention and @entity1067 related surgery. Improvements in outcomes with @entity16503 vs placebo were greatest in @entity1 with the highest baseline total prostate and transition zone volume, and transition zone index. In @entity1 with low (30 to less than 42 cc) and intermediate (42 to less than 58 cc) baseline total prostate volume the benefits of @entity16503 therapy were only significant in the intermediate (0.4 to less than 0.55) and high (0.55 to less than 1.0) transition zone index tertiles. CONCLUSIONS: Total prostate and transition zone volume, and the transition zone index are directly related to @entity1067 progression. The transition zone index may add value to transition zone volume alone for predicting outcomes. @entity16503 decreased transition and peripheral zone volume equally, supporting a known therapeutic role in @entity1067 and a possible preventive @entity263 .
